ClinicalTrials.gg
CompletedNCT01207492Updated Nov 10, 2026Results posted

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

A Phase 2 interventional study of nilotinib in Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor and Tenosynovial Giant Cell Tumor, sponsored by Andrew J. Wagner, MD, PhD. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Andrew J. Wagner, MD, PhD · Phase 2, Interventional, and Treatment

How we know

Updated Nov 10, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Synovitis, Pigmented Villonodular with a site in United States — none open to participants now, 4 under way, 3 of them phase 3. Synovitis, Pigmented Villonodular · United States.

Enrollment
10th of 12
17 · median 51
Started
2010
the only one that year
Phase 2
4 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
1 of 13
Andrew J. Wagner, MD, PhD

Among the 13 studies in Synovitis, Pigmented Villonodular with a site in United States, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2010, is one of 4 in phase 2, and was the 1st registered.

Synovitis, Pigmented Villonodular

20 studies on the registry are indexed under Synovitis, Pigmented Villonodular; 2 are open to participants now.

Browse Synovitis, Pigmented Villonodular studies →

Open to participants now

None of the 13 studies in Synovitis, Pigmented Villonodular with a site in United States is open now. The open studies under Synovitis, Pigmented Villonodular, anywhere →

Who these studies take

Of the 1 Synovitis, Pigmented Villonodular study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Synovitis, Pigmented Villonodular with a site in United States as a file.
02

Study summary

Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.

Read the detailed description
  • In this research study, each cycle of study drug dosing will last 4 weeks (28 days). During each cycle, participants will take nilotinib by mouth twice daily. During the first cycle, participants will come to the clinic on Days 1 and 8. For Cycles 2-4 and every 3 cycles thereafter, they will come to the clinic on Day 1.
  • The following tests and procedures will be performed at specific time points during study treatment: MRI or CT scans; physical examinations; vital signs; blood work; questionnaires and EKG.
  • Participants may continue in this research study for as long as they do not have serious side effects or their disease does not get worse.
03

Conditions studied

  • Pigmented Villonodular Synovitis
  • Diffuse-type Giant Cell Tumor
  • Tenosynovial Giant Cell Tumor

Keywords

  • nilotinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of recurrent PVNS ( or diffuse-type giant cell tumor or tenosynovial giant cell tumor) that is unresectable, , or for which the patient refuses surgical intervention
  • Progressive disease in the last 12 months, as demonstrated by imaging or clinical appearance of new tumors, in the opinion of the treating investigator
  • At least one site of according to 1.1 on MRI (or CT scan for metastatic disease)
  • Any number or type of prior systemic therapies, with the exception of known or suspected CSF1 receptor inhibitors as outlined in exclusion criteria below
  • 18 years of age or older
  • greater than 6 months
  • Performance Status of 0, 1 or 2
  • Normal organ and marrow function as defined in the protocol
  • less than or equal to 450 ms on 12-lead
  • Negative urine or serum pregnancy test within days of start of study drug administration for women of .
  • Women of childbearing potential and men must agree to use adequate prior to study entry, for the duration of study participation, and for 3 months following study drug discontinuation

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with known or suspected CSF1 receptor inhibitor, including nilotinib, imatinib, sunitinib, or sorafenib, or other approved or tyrosine kinase inhibitors used for treatment of diffuse-type giant cell tumor
  • Concurrent treatment with other investigational agents
  • Inability to tolerate or to MRI scanning for participants with localized disease
  • Impaired cardiac function
  • Current treatment with strong inhibitors that cannot either be discontinued or switched to a different medication prior to starting study drug
  • Current treatment with any medications that have the potential to prolong the and that cannot either be discontinued or switched to a different medication prior to starting study drug
  • Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug
  • Acute or chronic pancreatic disease
  • Acute or chronic liver disease
  • Another primary malignant disease requiring systemic treatment or radiation
  • History of significant congenital or acquired bleeding disorder unrelated to cancer
  • Major surgery within 28 days prior to Day 1 of the study
  • Treatment with other investigational agents within 28 days of day 1
  • History of non-compliance to medical regimens or inability to grant consent
  • Women who are pregnant or breastfeeding
  • Other comorbidities that would interfere with study participation or safety in the opinion of the investigator
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Nilotinib 200 mg taken as 400 mg twice daily, continuously

    Drug: nilotinib

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Progression Free Survival

    To estimate progression free survival at 6 months in participants with recurrent PVNS treated with nilotinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: 6 months

Secondary outcomes

  1. Overall Tumor Response Rate (OR)

    To determine overall tumor response rate \[% complete response (CR) + % partial response (PR) by RECIST 1.1\]. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a \>=30% decrease in the sum of the longest diameter of target lesions. Overall Response (OR) = CR + PR.

    Time frame: 2 years

  2. Clinical Benefit Rate

    To determine the clinical benefit rate \[% CR + % PR + % stable disease by RECIST 1.1\] at 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a \>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: 6 months

07

Results

Posted Jun 25, 2015

Participant flow

Participant flow — Overall Study
MilestoneNilotinib
Started17
Completed2
Not completed15
Withdrew: Withdrawal by subject7
Withdrew: Physician decision1
Withdrew: Progressive disease4
Withdrew: Toxicity2
Withdrew: Lost to follow-up1

Outcome measures

PrimaryPercentage of Participants With Progression Free Survival

To estimate progression free survival at 6 months in participants with recurrent PVNS treated with nilotinib. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Time frame:
6 months
Reported as:
Number · percentage of participants with PFS
Percentage of Participants With Progression Free Survival
percentage of participants with PFSNilotinib
Percentage of Participants With Progression Free Survival82 (57 to 96)
SecondaryOverall Tumor Response Rate (OR)

To determine overall tumor response rate \[% complete response (CR) + % partial response (PR) by RECIST 1.1\]. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a \>=30% decrease in the sum of the longest diameter of target lesions. Overall Response (OR) = CR + PR.

Time frame:
2 years
Reported as:
Number · percentage of participants
Overall Tumor Response Rate (OR)
percentage of participantsNilotinib
Overall Tumor Response Rate (OR)0 (0 to 20)
SecondaryClinical Benefit Rate

To determine the clinical benefit rate \[% CR + % PR + % stable disease by RECIST 1.1\] at 6 months. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR) is a disappearance of all target lesions. Partial Response (PR) is a \>=30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

Time frame:
6 months
Reported as:
Number · percentage of participants
Clinical Benefit Rate
percentage of participantsNilotinib
Clinical Benefit Rate47 (23 to 72)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib—2/17 (11.8%)17/17 (100%)
Most frequent serious events
Most frequent serious events
EventNilotinib
FatigueGeneral disorders and administration site conditions2/17
Electrocardiogram QT corrected interval prolongedInvestigations1/17
HypophosphatemiaMetabolism and nutrition disorders1/17
Rash maculo-papularSkin and subcutaneous tissue disorders1/17
Most frequent other events
Showing 10 of 53
Most frequent other events
EventNilotinib
NauseaGastrointestinal disorders9/17
Rash maculo-papularSkin and subcutaneous tissue disorders9/17
FatigueGeneral disorders and administration site conditions8/17
HeadacheNervous system disorders7/17
ConstipationGastrointestinal disorders5/17
Alanine aminotransferase increasedInvestigations5/17
Aspartate aminotransferase increasedInvestigations5/17
VomitingGastrointestinal disorders4/17
Upper respiratory infectionInfections and infestations4/17
MyalgiaMusculoskeletal and connective tissue disorders4/17

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nilotinib
<=18 years0
Between 18 and 65 years15
>=65 years2
Age, Continuous
Age, Continuous(years)Nilotinib
Mean45.35 ± 13.54
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female12
Male5
Region of Enrollment
Region of Enrollment(participants)Nilotinib
United States17
08

Study locations

7 sites
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • UT MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2010 to primary completion in Apr 2014, 43 months.

Results were first posted in Jun 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2010
First posted
Sep 23, 2010
StartActual
Sep 2010
Primary completionActual
Apr 2014
CompletionActual
Aug 2015
Results first posted
Jun 25, 2015
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Posted results revised
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01207492
Lead sponsor
Andrew J. Wagner, MD, PhD
Responsible party
Andrew J. Wagner, MD, PhD (Sponsor, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Sep 23, 2010
Start date
Sep 2010
Primary completion
Apr 2014
Completion
Aug 2015
Results posted
Jun 25, 2015
Last update
Nov 10, 2026

Study contacts

Andrew J. Wagner, MD, PhD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion